Real‐World Data of Second‐Line Amrubicin Monotherapy in Patients With Extensive‐Stage Small Cell Lung Cancer Who Received First‐Line Chemoimmunotherapy or Chemotherapy: A Multicenter Retrospective Study

Documenti analoghi

• Real‐World Study of EGFR‐TKI Rechallenge With Another TKI After First‐Line Osimertinib Discontinuation in Patients With EGFR‐Mutated Non‐Small Cell Lung Cancer: A Subset Analysis of the Reiwa Study
  di: Kei Sonehara, et al.
  Pubblicazione: (2024)
• Population III Supernovae as a dust factory I --- molecule formation and mixing/fallback in ejecta
  di: Chiaki, Gen, et al.
  Pubblicazione: (2025)
• Double novel integrated outside biliary stent and nasobiliary drainage catheter system placement for hilar biliary stricture
  di: Akihiro Sekine, et al.
  Pubblicazione: (2024)
• The space of marked Dyer systems, monotonicity, and continuity of growth rates
  di: Yukita, Tomoshige
  Pubblicazione: (2026)
• TP53 CpG Site Mutations Predict the Survival of First‐Line Chemoimmunotherapy in Advanced Lung Adenocarcinoma
  di: Lige Wu, et al.
  Pubblicazione: (2026)